# Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France

> **NCT01552005** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1000 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2D)

## Interventions

- **DRUG:** Saxagliptin

## Key facts

- **NCT ID:** NCT01552005
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2016-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01552005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01552005, "Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01552005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*